New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
08:36 EDTPTCTPTC Therapeutics named a new top pick at Credit Suisse
Credit Suisse said PTC Therapeutics is a new top pick following the recent CHMP recommendation. The firm expects PTC to launch Translarna in the EU in 2H and and views it as a potential billion-dollar drug. Shares are Outperform rated with a $40 price target.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:59 EDTPTCTNHS to wait on NICE to make call on PTC Therapeutics, BioMarin drugs
NHS England has set out its planned investment decisions for certain specialized services as part of its annual commissioning round. NHS England has agreed with the recommendations from CPAG that final funding decisions on the following two treatments should be made after NICE has concluded its Highly Specialized Technology Appraisal process: BioMarin Pharmaceutical's (BMRN) Vimizim for Morquio A Syndrome and PTC Therapeutics' (PTCT) Translarna for Duchenne muscular dystrophy. The decisions on those two drugs came among 39 proposed new investments that the group said were "carefully considered against the principles NHS England follows when making investment decisions." Reference Link
June 23, 2015
07:49 EDTPTCTPTC Therapeutics risk lowered by symposium, says Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use